| 3.18 0.49 (18.22%) | 03-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.28 |
1-year : | 5 |
| Resists | First : | 3.67 |
Second : | 4.28 |
| Pivot price | 2.81 |
|||
| Supports | First : | 2.81 |
Second : | 2.28 |
| MAs | MA(5) : | 2.64 |
MA(20) : | 2.9 |
| MA(100) : | 4.84 |
MA(250) : | 5.35 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 36.7 |
D(3) : | 23.8 |
| RSI | RSI(14): 55.3 |
|||
| 52-week | High : | 11.45 | Low : | 1.07 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RZLT ] has closed below upper band by 22.4%. Bollinger Bands are 55.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 56 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.66 - 3.67 | 3.67 - 3.68 |
| Low: | 2.85 - 2.86 | 2.86 - 2.88 |
| Close: | 3.16 - 3.18 | 3.18 - 3.2 |
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Wed, 25 Mar 2026
Rezolute (RZLT) Gains Upgrade Following Positive FDA Meeting - GuruFocus
Wed, 25 Mar 2026
Rezolute Shares Rise After FDA Signals Hope for Treatment Approval - timothysykes.com
Wed, 25 Mar 2026
Rezolute Stock Gains After FDA Meeting on Ersodetug Program Update - The Globe and Mail
Wed, 25 Mar 2026
Rezolute’s Shares Soar Despite Initial Obstacles in Trial Data - StocksToTrade
Wed, 25 Mar 2026
Rezolute (NASDAQ:RZLT) Stock Rating Upgraded by Wedbush - MarketBeat
Wed, 25 Mar 2026
FDA Review Puts Rezolute's Genetic Disorder Drug Path In Question - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 96 (M) |
| Shares Float | 66 (M) |
| Held by Insiders | 10.2 (%) |
| Held by Institutions | 96 (%) |
| Shares Short | 17,940 (K) |
| Shares Short P.Month | 18,890 (K) |
| EPS | -0.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.23 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -44.1 % |
| Return on Equity (ttm) | -74.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.93 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -77 (M) |
| Levered Free Cash Flow | -46 (M) |
| PE Ratio | -3.42 |
| PEG Ratio | 0 |
| Price to Book value | 2.58 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|